Druckenmiller Increases Teva Holdings to 16.6 Million Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Increased Drug Holdings: Stanley Druckenmiller began accumulating shares of Teva Pharmaceutical in the second half of 2024, increasing his holdings to 16.6 million shares by Q3 2025, reflecting confidence in the company's future growth prospects.
- Legal Issues Resolved: Teva settled litigation with 48 states in early 2023, alleviating financial pressures and allowing investors to refocus on the company's innovative capabilities and market potential.
- Innovation Shift: Under new leadership, Teva is transitioning towards novel drug development, with its tardive dyskinesia drug Austedo expected to generate over $2 billion in global sales by 2025, significantly enhancing profitability.
- Financial Improvement: Teva has successfully halved its net debt from $35 billion to $14.6 billion over the past nine years, demonstrating substantial financial improvement that lays a solid foundation for future investments and growth.
TEVA
$31.54+Infinity%1D
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.210
Low
28.00
Averages
29.25
High
32.00
Current: 31.210
Low
28.00
Averages
29.25
High
32.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
